INT216983

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 5
Disease Relevance 1.11
Pain Relevance 0.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Lpar4) signal transduction (Lpar4) plasma membrane (Lpar4)
signal transducer activity (Lpar4)
Anatomy Link Frequency
platelet 2
macrophages 1
neurite 1
ovary 1
Lpar4 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 68 100.00 Very High Very High Very High
cytokine 76 86.16 High High
agonist 72 76.00 Quite High
cva 4 33.56 Quite Low
Pain 17 17.52 Low Low
Inflammation 23 15.68 Low Low
fibrosis 36 5.00 Very Low Very Low Very Low
Neuropathic pain 32 5.00 Very Low Very Low Very Low
dorsal root ganglion 16 5.00 Very Low Very Low Very Low
metalloproteinase 16 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Neuroblastoma 4 97.48 Very High Very High Very High
Shock 4 95.24 Very High Very High Very High
Coronary Artery Disease 4 84.96 Quite High
Cancer 98 75.88 Quite High
Metastasis 40 75.44 Quite High
Targeted Disruption 61 73.56 Quite High
Hypercalcemia 4 64.72 Quite High
Breast Cancer 12 60.20 Quite High
Osteoporosis 12 55.64 Quite High
Bordatella Infection 8 51.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This response is likely to be mediated through LPA4, which, in contrast to the EDG family receptors, elevates cAMP and is highly expressed in the ovary (Noguchi et al., 2003).
Positive_regulation (mediated) of LPA4 in ovary
1) Confidence 0.31 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.58 Pain Relevance 0.03
In patients whose platelets do not respond to LPA, LPA4 mRNA is increased sixfold over platelets from patients that are LPA-responsive.
Positive_regulation (increased) of LPA4 in platelets
2) Confidence 0.31 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.27 Pain Relevance 0
The former compound but not the latter is also a weak antagonist of LPA4 (Ki 741 nM), yet both inhibited platelet responses to LPA.
Positive_regulation (antagonist) of LPA4 in platelet associated with antagonist
3) Confidence 0.22 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0 Pain Relevance 0.10
The brain expresses relatively high levels of LPA4; and it has been shown, using heterologous expression in B103 neuroblastoma cells, to cause LPA-dependent growth cone collapse and neurite retraction through G12/13-RhoA-Rho-associated kinase (ROCK) activation (Lee et al., 2007).
Positive_regulation (levels) of LPA4 in neurite associated with neuroblastoma and shock
4) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.25 Pain Relevance 0
output from murine RAW 264.7 macrophages both in the absence and presence of LPS [79]; the purinergic receptor responsible for this effect in RAW cells is unknown.
Positive_regulation (responsible) of purinergic receptor in macrophages
5) Confidence 0.00 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2096759 Disease Relevance 0 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox